Paul Yaworsky

Paul Yaworsky is the founding CSO of Mediar Therapeutics. He joined Mediar from Pfizer, where he spent more than 20 years focused on drug discovery and development. At Pfizer, Paul created the initial scientific and business plan for fibrosis research. Most recently, he served as COO, Inflammation & Immunology Research, where he led strategy and operations for the research unit from early discovery into the clinic including first-in-human through Phase 2 proof-of-concept for both biologics and small molecule approaches for Inflammation and Immunology assets.

A native of Canada, Paul holds a Ph.D. in Molecular Neuroscience from the Mayo Clinic Graduate School of Biomedicine and a BSc in Molecular Genetics from the University of Toronto.